FY25 Appendix 4E and Preliminary Final Report

• Revenue up 21.7% to $3,613,887,000
• Underlying EBITDA up 79.5% to $95,203,000
• Profit after tax up 151.5% to $20,574,000

Paragon Care Limited reported a solid underlying result for the year ended 30 June 2025. Revenue increased by 22% to $3,613,887,000 and gross margin was up 84% to $324,001,000. Underlying EBITDA increased by 80% to $95,203,000, reflecting the organic growth of the Group's position along with full-year earnings contributions from the reverse acquisition of CH2 Holdings and the acquisition of Oborne Health Services. The profit for the Group after providing for income tax amounted to $20,574,000, up 151.5% from the prior year. The acquisition of CH2 Holdings in June 2024 was a transformative transaction that enabled Paragon Care to leverage expansion into both companies' healthcare wholesaling and distribution networks across Australia, New Zealand and Asia, capitalizing on and strengthening the combined market presence and operational capabilities in these growing markets. The application of the reverse acquisition accounting guidance resulted in CH2 Holdings being accounted for as the accounting acquirer, with the comparative results for the year ended 30 June 2024 comprising the results of CH2 Holdings for the full year and the results of Paragon Care subsequent to the completion of the acquisition.

The Group delivered a solid underlying result during the year ended 30 June 2025, with revenue up 22% to $3,613,887,000 and underlying EBITDA up 79.5% to $95,203,000.